Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | Novel strategies to optimize CAR-T therapy in myeloma

Paola Neri • 19 Apr 2021
COMy 2021
Multiple Myeloma CAR-T
CARTITUDE-1

Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discusses the promise of novel CAR-T therapy strategies for the treatment of multiple myeloma. Several approaches are under investigation that may improve efficacy and response durability. These include the use of allogenic CAR-T products, dual targeting, and optimized manufacturing. CAR T-cell therapy and immunotherapy remain in the spotlight as new exciting findings continue to emerge. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

Disclosures

Speaker bureau/honoraria: BMS, Janssen
Consulting fees: BMS, Janssen

More from Paola Neri

1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024
Resistance mechanisms mediated by the microenvironment in multiple myeloma
Charlotte Pawlyn et al. • 15 Apr 2023
1:51
Optimizing immunotherapy in myeloma: tumor profiling, mutations & characterizing T-cell fitness
Paola Neri • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals